Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02743546
Title Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

mantle cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

chronic lymphocytic leukemia

Therapies

Ibrutinib + JNJ-64052781

Age Groups: adult
Covered Countries


No variant requirements are available.